Protalix BioTherapeutics Profit Margin

Protalix BioTherapeutics (PLX) currently reports a profit margin of 23.5% as of June 2026. That compares with 10.13% in the prior-year period — up 132.0% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore Protalix BioTherapeutics's profit margin history and peer comparisons.

Protalix BioTherapeutics's profit margin increased from 10.13% to 23.5% — a 132.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Protalix BioTherapeutics's profit margin of 23.5% is higher than the Healthcare sector average of 14.34%. That is roughly 63.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Protalix BioTherapeutics's current 23.5% should be judged against Healthcare norms (sector average: 14.34%) and against PLX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 23.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for Protalix BioTherapeutics, and consider following PLX for alerts when major investors trade the stock.